Jill Wu, an analyst from CMB International Securities, maintained the Buy rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990 – Research Report). The associated price target was raised to HK$299.93.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jill Wu has given her Buy rating due to a combination of factors including Sichuan Kelun-Biotech’s impressive financial performance and strategic advancements in their drug pipeline. The company demonstrated strong revenue growth in 2024, primarily driven by milestone payments from global partnerships and the launch of new drugs, which reflects its robust collaboration efforts and innovative product development.
Moreover, the company’s focus on commercializing next-generation ADC therapeutics, particularly the Sac-TMT drug, which has shown significant clinical benefits, supports the positive outlook. The expansion of their commercial team and the strategic utilization of Kelun Pharma’s industry resources further bolster confidence in achieving substantial sales targets. Additionally, Kelun-Biotech’s ongoing innovation in ADC strategies across oncology and non-oncology fields highlights its potential for continued growth and market leadership.